# Obesity Hypoventilation Syndrome

## Definition and Epidemiology

### Diagnostic Criteria

Obesity hypoventilation syndrome is defined by a triad of obesity (BMI of 30 kg/m2 or greater), awake daytime hypercapnia (PaCO2 of 45 mmHg or greater), and sleep-disordered breathing (either OSA or sleep-related hypoventilation), after exclusion of other causes of hypoventilation. Alternative causes that must be excluded include COPD (though coexistence is common), neuromuscular disease, chest wall deformity, severe hypothyroidism, and medications such as opioids and benzodiazepines.

### Epidemiology

The prevalence of OHS is estimated at 0.3-0.4% of the general population, 10-20% of obese patients with OSA, and 8-20% of hospitalized obese patients. Approximately 90% of OHS patients have concomitant OSA, while the remaining 10% have sleep-related hypoventilation without discrete obstructive events. OHS is substantially underdiagnosed, and many patients present for the first time with acute hypercapnic respiratory failure. Untreated 5-year mortality is approximately 25-45%, significantly higher than matched obese patients without hypoventilation.

### Pathophysiology

The pathophysiology of OHS is multifactorial, involving the convergence of respiratory mechanics impairment, central ventilatory drive blunting, and sleep-disordered breathing. The massive increase in abdominal and chest wall mass reduces functional residual capacity and expiratory reserve volume, elevates the diaphragm, reduces respiratory system compliance, increases the work of breathing, and produces V/Q mismatch through small airway closure at low lung volumes. Central hypoventilation is driven by a blunted hypercapnic ventilatory response (HCVR) and leptin resistance. Leptin, which normally stimulates ventilation, is produced in excess in obesity, but central signaling is impaired, paralleling the metabolic leptin resistance seen in obesity-related metabolic syndrome. Sleep-disordered breathing, primarily OSA, causes intermittent nocturnal hypercapnia that over time triggers renal bicarbonate retention to maintain pH, resetting CO2 chemoreceptor sensitivity upward and resulting in chronic daytime hypercapnia.

## Clinical Presentation

### Symptoms

Patients with OHS experience excessive daytime sleepiness that is often more severe than in eucapnic obese OSA. Morning headaches reflect nocturnal CO2 retention, and cognitive impairment is common. Dyspnea on exertion and exercise intolerance are prominent. Loud snoring and witnessed apneas indicate the OSA component. Lower extremity edema and signs of right heart failure (cor pulmonale) develop in advanced disease.

### Physical Examination

Physical findings include morbid obesity (mean BMI at diagnosis approximately 45 kg/m2), central cyanosis, plethoric facies, signs of cor pulmonale (elevated JVP, peripheral edema, hepatomegaly, loud P2), and restricted chest wall expansion. Concurrent obesity-related comorbidities including type 2 diabetes, hypertension, and dyslipidemia are frequently present.

### Laboratory and Diagnostic Findings

Arterial blood gas analysis reveals elevated PaCO2 (45 mmHg or greater) and elevated bicarbonate reflecting chronic metabolic compensation, typically 28-35 mEq/L. Elevated serum bicarbonate (27 mEq/L or greater) on a basic metabolic panel serves as a screening clue. Pulmonary function testing demonstrates a restrictive pattern with markedly reduced expiratory reserve volume, often below 50% predicted. Polycythemia reflects chronic hypoxemia. PSG reveals OSA in approximately 90% of cases, often severe with AHI exceeding 30, and sleep hypoventilation (CO2 rise of 10 mmHg or more above the awake supine value during sleep) in the remaining 10%. Echocardiography may demonstrate pulmonary hypertension and RV dilation or dysfunction in advanced cases.

<image>A pathophysiology diagram of obesity hypoventilation syndrome showing the interconnected mechanisms. Center: obese patient silhouette. Pathway 1 (Mechanics): show massive abdominal/chest wall adiposity compressing the diaphragm, reducing FRC/ERV, causing small airway closure and V/Q mismatch. Pathway 2 (Central drive): show brainstem respiratory center with blunted CO2 chemoreceptor sensitivity and leptin resistance (elevated serum leptin but impaired central signaling). Pathway 3 (Sleep-disordered breathing): show upper airway collapse (OSA) causing intermittent nocturnal hypercapnia -> renal HCO3 retention -> chemoreceptor reset -> chronic daytime hypercapnia. Converging arrows: all three pathways contribute to awake hypercapnia. Show downstream consequences: pulmonary hypertension, cor pulmonale, polycythemia, metabolic syndrome. Use a circular vicious cycle diagram connecting these mechanisms.</image>

## Diagnosis

### Diagnostic Approach

The diagnostic approach proceeds through four steps. First, obesity and hypercapnia are identified through ABG or venous blood gas with serum bicarbonate of 27 mEq/L or greater as screening. Second, other causes of hypercapnia are excluded, including COPD, neuromuscular disease, chest wall disease, and medications. Third, a sleep study (PSG preferred) characterizes the sleep-disordered breathing pattern as OSA versus sleep hypoventilation. Fourth, complications are assessed through echocardiography, PFTs, and CBC for polycythemia.

### Distinguishing OHS from Eucapnic Obese OSA

Serum bicarbonate of 27 mEq/L or greater in an obese patient with OSA achieves a sensitivity of 92% for OHS with a specificity of approximately 50%. ABG confirmation requires a PaCO2 of 45 mmHg or greater while the patient is awake, breathing room air, seated, and at rest. Eucapnic OSA is distinguished by normal daytime PaCO2 despite severe OSA, without the renal compensation seen in OHS.

### Phenotypes

| Feature | OHS with OSA (90%) | OHS without OSA (10%) | Eucapnic Obese OSA |
|---------|-------------------|----------------------|-------------------|
| AHI | Typically > 30 | < 5 (no obstructive events) | Variable |
| Sleep pattern | Obstructive apneas/hypopneas | Sustained hypoventilation | Obstructive events only |
| Daytime PaCO2 | >= 45 mmHg | >= 45 mmHg | Normal |
| Serum HCO3 | >= 27 mEq/L | >= 27 mEq/L | Normal |
| First-line PAP | CPAP (Pickwick study) | Bilevel PAP with backup rate | CPAP |
| Prognosis | Improved with PAP | Worse; may need more aggressive ventilation | Better than OHS |

OHS with OSA (90% of cases) demonstrates a dominant obstructive component with AHI typically exceeding 30. OHS without OSA (10%) features pure sleep hypoventilation with sustained hypoventilation during sleep without discrete obstructive events, often carries a worse prognosis, and may respond better to bilevel PAP with a backup rate.

## Management

### Positive Airway Pressure Therapy

CPAP is effective in OHS with predominant OSA, improving daytime PaCO2, sleepiness, and quality of life. The Pickwick study demonstrated that CPAP and bilevel PAP were equally effective for improving PaCO2, sleepiness, and polysomnographic outcomes at 2 months in OHS patients with severe OSA, and both were superior to lifestyle modification alone. Bilevel PAP in spontaneous/timed (ST) mode is preferred for OHS without significant OSA, OHS with persistent hypoventilation on CPAP, or initial ICU management. Typical settings include IPAP 16-24 cmH2O, EPAP 6-10 cmH2O, and a backup rate of 12-14, titrated to improve SpO2, reduce transcutaneous CO2, and achieve adequate tidal volume. Average volume-assured pressure support (AVAPS) auto-adjusts IPAP to maintain a target tidal volume and may improve adherence and nocturnal ventilation. PAP may be initiated empirically with APAP or auto-BiPAP if in-laboratory titration is not immediately available. Adherence is critical, with a minimum of 4 hours per night and ideally more than 6 hours recommended.

### Weight Management

Weight management is the cornerstone of long-term OHS management and is potentially curative. A 10% weight loss produces significant improvement in PaCO2 and respiratory mechanics. Behavioral and dietary interventions have limited long-term success in morbid obesity. Bariatric surgery is the most effective intervention for sustained weight loss and can resolve OHS in the majority of patients. Indications include BMI of 40 or greater, or BMI of 35 or greater with comorbidities. Perioperative risk is higher in OHS patients, necessitating optimization of PAP therapy preoperatively and close perioperative monitoring. GLP-1 receptor agonists, including semaglutide (STEP trials: 15-17% weight loss) and tirzepatide (SURMOUNT trials: 20-25% weight loss), represent an emerging role in OHS management. While no dedicated OHS trial has been conducted, the magnitude of weight loss achieved with these agents is expected to significantly improve respiratory mechanics and ventilatory control.

### Supplemental Oxygen

Supplemental oxygen may be needed during sleep or with exertion if persistent hypoxemia exists despite optimized PAP therapy. Oxygen monotherapy without PAP must be avoided as it can worsen hypercapnia by blunting the hypoxic ventilatory drive. The SpO2 target should be 88-92% when concurrent hypercapnia is present.

### Pharmacotherapy

No medication is first-line for OHS. Medroxyprogesterone, a respiratory stimulant, has limited evidence with modest PaCO2 reduction, and its side effects, including DVT risk, limit clinical utility. Acetazolamide, a carbonic anhydrase inhibitor that creates metabolic acidosis to stimulate ventilation, may serve as an adjunct in selected cases but has limited data in OHS.

<image>A treatment algorithm for obesity hypoventilation syndrome. Start with confirmed OHS diagnosis (BMI >= 30 + PaCO2 >= 45 + SDB after exclusion of other causes). First branch: acute presentation (hypercapnic respiratory failure) vs. stable outpatient presentation. Acute: NIV (bilevel PAP ST mode, IPAP 16-24, EPAP 6-10, backup rate 12-14) in ED/ICU; avoid intubation if possible; monitor ABG at 1-2 hours; if improving, continue NIV and transition to ward. Stable: sleep study (PSG) to characterize SDB phenotype. If OSA-predominant (AHI > 30): trial CPAP first (Pickwick study evidence). If persistent hypoventilation on CPAP or OHS without OSA: bilevel PAP with backup rate or AVAPS. Concurrent long-term management: weight loss (lifestyle + GLP-1 RA + bariatric surgery referral if eligible), treat comorbidities (diabetes, HTN, PH), supplemental O2 if needed. Show monitoring schedule: PaCO2 trend, sleep study follow-up, weight trajectory, echocardiography for PH.</image>

## Acute Hypercapnic Respiratory Failure in OHS

### Presentation

Acute hypercapnic respiratory failure is the most common presentation of previously undiagnosed OHS. It is typically triggered by intercurrent illness (pneumonia, heart failure exacerbation), the post-surgical state, or sedative and opioid administration. The presentation is one of acute-on-chronic hypercapnic respiratory failure, and the pH may be only mildly acidotic (7.25-7.35) due to chronic bicarbonate compensation.

### Acute Management

Non-invasive ventilation with bilevel PAP is first-line, and intubation should be avoided if possible. Initial settings include IPAP 16-20 cmH2O titrated upward as tolerated, EPAP 6-8 cmH2O, and FiO2 to target SpO2 88-92%. ABG should be monitored at 1-2 hours, with improvement in pH indicating success and failure to improve prompting pressure escalation or consideration of intubation. If intubation becomes necessary, a difficult airway should be anticipated given obesity and a short neck, a ramped position should be used, and an experienced operator is essential. Excessive supplemental oxygen must be avoided as it worsens V/Q mismatch and hypercapnia. The precipitant should be treated directly. Transition to nocturnal PAP therapy must occur before discharge, and patients should not be discharged without established home PAP.

## Prognosis and Complications

### Cardiovascular Consequences

Pulmonary hypertension is present in 30-60% of OHS patients, correlating with the severity and duration of hypoxemia and hypercapnia. Cor pulmonale from chronic pulmonary hypertension may reverse with effective PAP therapy and weight loss. Atrial fibrillation has increased prevalence. Cardiovascular mortality is the primary driver of excess mortality in OHS.

### Treatment Outcomes

PAP therapy reduces PaCO2 within weeks and improves pulmonary hypertension, polycythemia, sleepiness, and quality of life. Hospitalization rates are significantly reduced with adherent PAP use. Weight loss through bariatric surgery may normalize PaCO2 and eliminate the need for PAP in successful cases.

## Key Clinical Pearls

- Serum bicarbonate >= 27 mEq/L in an obese patient with suspected or confirmed OSA is a sensitive screening test for OHS; always check an ABG to confirm daytime hypercapnia
- CPAP is as effective as bilevel PAP for OHS patients with predominant severe OSA (Pickwick study); bilevel is reserved for those with inadequate response to CPAP, OHS without significant OSA, or acute respiratory failure
- Never prescribe supplemental oxygen alone (without PAP) for OHS; it can worsen hypercapnia by suppressing the hypoxic ventilatory drive
- OHS frequently presents as undiagnosed acute hypercapnic respiratory failure; initiate NIV early and establish home PAP therapy before hospital discharge
- GLP-1 receptor agonists (semaglutide, tirzepatide) producing 15-25% weight loss may revolutionize OHS management; though no OHS-specific trial exists yet, the weight loss achieved addresses the fundamental pathophysiology

## References
1. Masa JF, Mokhlesi B, Benitez I, et al. Long-term clinical effectiveness of continuous positive airway pressure therapy versus non-invasive ventilation therapy in patients with obesity hypoventilation syndrome: a multicentre, open-label, randomised controlled trial. Lancet. 2019;393(10182):1721-1732. (Pickwick)
2. Mokhlesi B, Masa JF, Brozek JL, et al. Evaluation and Management of Obesity Hypoventilation Syndrome: An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2019;200(3):e52-e73.
3. Piper AJ, Grunstein RR. Obesity hypoventilation syndrome: mechanisms and management. Am J Respir Crit Care Med. 2011;183(3):292-298.
4. Nowbar S, Burkart KM, Gonzales R, et al. Obesity-associated hypoventilation in hospitalized patients: prevalence, effects, and outcome. Am J Med. 2004;116(1):1-7.
5. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. (SURMOUNT-1)